Ronjon Nag
Co-Founder, CEO @ Cellmania
San Francisco, United States
Ronjon Nag is a seed investor at Cellmania in San Francisco focused on Artificial Intelligence and Software. Dr. Ronjon Nag is CEO/Co-Founder of Cellmania & R42 Group, a leading wireless applications company. Dr. Nag, is an acknowledged authority in the mobile industry, having been featured on the cover of Fortune and involved in the development of, and holding patents in, wireless applications, user interfaces and new m-commerce distributionmethods of mobile applications and devices. Previously a Vice President and General Manager at Motorola responsible for smart mobile technologies developed in the Lexicus Division and Motorola Human Interface Laboratories worldwide, hundreds of millions of Motorola devices have shipped with technology developed under his leadership - voice recognition, handwriting recognition and predictive text key systems. Previously Dr. Nag was CEO/founder of Lexicus, a pioneer of speech and handwriting recognition technology, acquired by Motorola in 1993. Dr. Nag holds a Ph.D. from Cambridge University (speech recognition research), was a Harkness Fellow at Stanford University (neural network research), has an MBA from MIT, and a 1st class Honours degree of Birmingham University, UK (electrical engineering).
- Total investments:
- 14
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Ronjon Nag invests in
Stages Ronjon Nag invests in
Countries Ronjon Nag invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.2M–$13M
- Pre-Seed
- $472k–$2M
Investment Focus
Industry
- Artificial Intelligence 6 (43%)
- Software 3 (21%)
- Health Care 3 (21%)
- Life Science 3 (21%)
- Biotechnology 3 (21%)
Stage
- Seed 5 (36%)
- Pre-Seed 4 (29%)
- Series B 1 (7%)
- Series C 1 (7%)
- Convertible Note 1 (7%)
Country
- United Kingdom 5 (36%)
- United States 3 (21%)
- Canada 1 (7%)
- Austria 1 (7%)
- Germany 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Stamp Free
|
Stamp Free operates as a digital postage stamp company that provides postage solutions. The company provides an app that allows personal and business customers to buy stamps or digital postage directly on their mobile phones and then post their letters or parcels in the normal way. | $1.4M / Venture - Series Unknown / May 19, 2026 | |
Soopra.AI
|
Soopra is a platform that allows experts to create AI personas to interact with their audiences 24/7, providing a new, scalable way to monetize their knowledge. | $1M / Pre-Seed / May 14, 2025 | |
Healx
|
Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AItechnology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact. Founded in Cambridge, UK, in 2014 by Dr Tim Guilliams (a Biochemical Engineer and tech entrepreneur) and Dr David Brown (co-inventor of Viagra and former Global Head of Drug Discovery at Roche), Healx has raised $70 million to date. For more information, visit www.healx.io. | $47M / Series C / Aug 01, 2024 | |
Concr
|
ConcR’s software integrates a breadth of data into a model to predict how and why a cancer therapy will behave | $1.5M / Seed / Mar 31, 2023 | |
WiseWorks
|
WiseWorks is a meeting automation platform helping corporate governance professionals reduce the time they spend on costly tasks. | $1.2M / Seed / Jul 04, 2022 | |
Molecule
|
Molecule is a software platform used to decentralise intellectual property development in the biotech industry. The company was founded in 2020 by Paul Kohlhaas and Tyler Golato and is headquartered in Schaffhausen, Switzerland. | $12.7M / Seed / Jun 13, 2022 | |
Exogene
|
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M / Pre-Seed / Apr 25, 2022 | |
|
Exogene
|
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M / Pre-Seed / Apr 25, 2022 | |
|
Exogene
|
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M / Seed / Apr 25, 2022 | |
Celeris Therapeutics
|
Celeris Therapeutics is a deep learning company that uses innovative, computer-based methods to degrade undruggable targets. The platform Celeris One exploits the potential of degrader technologies with accurate predictions of biomolecular interactions and the expansion of chemical space.Celeris One uses methods such as Graph RepresentationLearning, Active Learning, Data Augmentation, and Generative Models to expand the chemical space and leverage sparse and heterogeneous data. This leads to the design of Heterobifunctional and Glue Degraders, as well as Small Molecules. | $471.5K / Pre-Seed / Mar 28, 2021 | |
| See all 14 investments → | |||
Co-Investors
About Cellmania
Cellmania Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ronjon Nag
Co-Founder, CEO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Ronjon Nag invest in?
Ronjon Nag invests primarily in Artificial Intelligence, Software and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 14 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Ronjon Nag's check size?
Ronjon Nag typically joins rounds of $1.2M–$13M at Seed and $472k–$2M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ronjon Nag participates in.
How do I contact Ronjon Nag?
Public channels for Ronjon Nag include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ronjon Nag last invest?
The most recent investment recorded for Ronjon Nag closed in May 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
